Unbiased Analysis of Today's Healthcare Issues

First biosimilar hits the market

Written By: Jason Shafrin - Jul• 24•14

Making a generic version of a single molecule drug is fairly straightforward.  Making a replica of a biologic treatment, however, is not.  Nevertheless, Congress signed into law the Biologics Price Competition and Innovation Act of 2009 (BPCI Act) to create a fast-track approval process for biological products that are demonstrated to be highly similar an FDA-approved biological product.  These products are known as biosimilars.

Today, this legislation has bore fruit.   FierceBiotech reports:

The FDA accepted Novartis’ application to sell a knockoff of Amgen’s biological treatment Neupogen, making the company a pioneer among those looking to capitalize on a soon-to-come U.S. market for biosimilars that is expected to explode.

Novartis is the first to file for a U.S. biosimilar approval under the FDA’s newly created pathway, according to the company, looking to market its take on a treatment for patients with low white blood cell counts that brought in $1.4 billion for Amgen last year. The drug, developed as filgrastim, is designed to prevent fever and infections in cancer patients taking chemotherapies that hamper bone marrow activity.

Is this a breakthrough? Yes and no. Although biosimilars are new to the US, Sandoz (the generic division of Novartis) already sells three biosimilar drugs, including filgrastim, in about 60 other countries.

You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

Leave a Reply

Your email address will not be published. Required fields are marked *